Navigation Links
FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
Date:6/30/2008

WOODCLIFF LAKE, N.J., June 30 /PRNewswire/ -- Eisai Corporation of North America, a wholly-owned subsidiary of Tokyo-based Eisai Co., Ltd., announced today that the Food and Drug Administration (FDA) has approved ACIPHEX (rabeprazole sodium) 20 mg for the short-term (up to eight weeks) treatment of gastroesophageal reflux disease (GERD) in adolescents ages 12 and above.

Included in the submission was a 12-week, multi-center, open-label, randomized, parallel-group study of 111 adolescent GERD patients. In this study, ACIPHEX was well tolerated in adolescent subjects, with a safety profile similar to that of adults. The adverse events reported without regard to relationship to ACIPHEX that occurred in greater than or equal to 2 percent of 111 patients were headache (9.9 percent), diarrhea (4.5 percent), nausea (4.5 percent), vomiting (3.6 percent) and abdominal pain (3.6 percent). Efficacy results demonstrated that once-daily treatment with ACIPHEX 20 mg for eight weeks reduced the severity and frequency of GERD symptoms compared to symptoms prior to treatment.

ACIPHEX was discovered and developed by Eisai and is copromoted in the United States with PriCara(R), a Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

About ACIPHEX(R) (rabeprazole sodium)

ACIPHEX(R) is a prescription medication. ACIPHEX 20 mg tablet once daily is approved for use in adults:

-- for the short-term (4 to 8 weeks) treatment in the healing and symptom relief of damaging (erosive) Gastroesophageal Reflux Disease (GERD).

-- to maintain healing of damage (erosions) and relief of heartburn symptoms with GERD. ACIPHEX has not been studied for treatment lasting longer than 12 months (1 year).

-- for the treatment of day-time and night-time heartburn and other symptoms that happen with GERD.

ACIPHEX 20 mg once daily is now also indicated for adolescents ages 12 and above for the short-term treatment (up to 8 weeks) for heartburn and ot
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
4. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
5. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
6. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
7. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
8. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
9. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
10. Medicare Approves in Home Sleep Apnea Testing
11. 3SBio Inc. Approves Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 Lawrence Livermore scientists ... Thomson Reuters list of " The World's Most Influential ... of the 3,000 researchers who were identified by analyzing ... those who published the highest-impact work (2002-2012 and 2012-2013). ... on combustion modeling . , "This recognition is ...
(Date:7/25/2014)... TEL AVIV, Israel , July 25, 2014 /PRNewswire/ ... a clinical-stage biopharmaceutical company focused on the development and ... of liver diseases and cholesterol gallstones, today announced financial ... First Half 2014 Financial Summary: , Reported ... 30, 2014, compared with $137,000 at December 31, 2013.  ...
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Xybion Corporation, ... for global corporations operating in highly regulated industries, ... first annual Global User Group Conference, Xybion International ... Philadelphia, Pennsylvania at the Sheraton ... http://photos.prnewswire.com/prnh/20140724/130263 This year,s conference ...
(Date:7/25/2014)... July 25, 2014 At the request ... granted a 60-day extension for the public comment period ... Rule for Model Aircraft established by Congress as part ... The 60-day extension establishes the new deadline for comments ... Department of Transportation/FAA notice published in the Federal Register ...
Breaking Biology Technology:Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3FAA Grants Comment Extension at the Request of AMA 2
... 31 Micromet, Inc.,(Nasdaq: MITI ), a ... antibody-based products for cancer, inflammation and,autoimmune diseases, today ... Officer of Micromet, will present at the Acumen ... New York, on,Wednesday, November 7, 2007 at 9:50am ...
... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) announced today that ... 9th Annual Healthcare Conference on Tuesday,November 6, 2007, at ... being,held at the New York Palace Hotel. Steve ... Inc. will present an overview of Anadys and its ...
... Product Sales ($97.4, Million, Up 17% Versus Prior Year) and Total Revenues ($101.7 Million, Up ... 10%) - ... Full-Year EPS of $1.50 to $1.52, Revenues of $400 to $402 ... Million -, SAN DIEGO, Oct. 30 Gen-Probe Incorporated,(Nasdaq: ...
Cached Biology Technology:Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007 2Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference 2Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 2Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 3Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 4Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 5Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 6Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 7Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 8Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 9Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 10Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 11Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 12Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 13Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 14
(Date:7/24/2014)... Invertebrate numbers have decreased by 45% on average over ... doubled, reports a study on the impact of humans ... the enormous benefits invertebrates such as insects, spiders, crustaceans, ... pollination and pest control for crops, decomposition for nutrient ... published in Science and led by UCL, ...
(Date:7/24/2014)... of 3.5 billion years of evolutionary trial and error, ... it may be reaching a tipping point. , In ... data published in Science , an international team ... animals is contributing to what appears to be the ... event. , Since 1500, more than 320 terrestrial vertebrates ...
(Date:7/24/2014)... Albert Einstein College of Medicine of Yeshiva ... Fox Foundation for Parkinson,s Research to translate a basic ... drug discovery project will test chemical compounds on a ... drug that acts on an underlying cause of the ... many people manage their symptoms, we are eager to ...
Breaking Biology News(10 mins):Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3
... reveals the genetic identity of human immunodeficiency virus (HIV), ... The finding provides important clues in the ongoing ... the University of Alabama at Birmingham (UAB). The UAB ... a few lead to sexual transmission. Earlier studies ...
... nervous system disorders such as Parkinsons disease, cardiovascular disorders ... in afflicted tissue and in aging cells, scientists have ... by reactive oxygen molecules, including the notorious free radicals ... and attack cellular proteins, nucleic and fatty acids. ...
... biomechanics and physiology from six universities, led by ... Technologys Media Lab, refute scientific claims that the ... African bilateral amputee track athlete, provide him with ... conclusions were based on data collected at the ...
Cached Biology News:HIV infection stems from few viruses 2Biosensor for measuring stress in cells 2Breaking news: Study revives Olympic prospects for amputee sprinter 2Breaking news: Study revives Olympic prospects for amputee sprinter 3